The biopharma industry’s business model now depends structurally and irreversibly on multi-party execution. Scientific, regulatory, political, and commercial conditions have converged to create unprecedented interdependence. Modalities are more diverse. Clinical execution is more distributed. Regulatory frameworks demand more evidence, more post-market monitoring, and more real-world data. Supply chains cross continents. Commercial models rely on precision engagement, specialty distribution, and coordinated access strategies. Alliances no longer supplement corporate strategy; in many cases, they are the corporate strategy.

In this environment, hierarchical leadership no longer proves effective. Competitive advantage no longer depends only on the scale of internal capabilities; it also depends on the collaborative capability of those who lead the organization.

The Collaboration Gap in the C-Suite

What makes this shift especially challenging is the gap between the strategic need for C-suite collaboration and the collaborative behavior many executive teams actually exhibit. Gartner’s research on C-suite dynamics reveals that only 31 percent of senior executives view their peers as their primary team.[1] Most identify instead with their functional domain—finance, commercial, R&D, manufacturing—rather than with the corporate leadership body. This functional identity fragments strategic execution, slows decision-making, and undermines the leadership coherence required for success today. The organizational leadership system amplifies this problem: companies often promote executives for technical excellence rather than for cross-boundary leadership capability, and organizations evaluate them with metrics that reward functional optimization rather than enterprise value. It is therefore unsurprising that only a third of CEOs say their C-suite is prepared for the challenges ahead.

This paper rests on a core cascading assumption: the collaborative capability of the C-suite shapes the collaborative capability of executives who serve on Joint Steering Committees (JSCs), and the JSCs in turn influence how effectively alliance teams function and deliver value. This pathway—executive → governance → alliance performance—is the logical and execution-oriented connection through which collaboration becomes a strategic advantage.

Collaboration as Strategic Discipline, Not Soft Skill

This shift has elevated an uncomfortable but unavoidable truth: the organization’s collaborative capability limits biopharma performance as much as scientific potential does. Stakeholders often mistake collaboration at the C-suite level for a managerial style or a set of values. In reality, leaders must treat collaboration as a strategic discipline—one that determines whether a company can integrate across silos, align across partners, and maintain coherence across the governance systems that guide its alliances. Collaboration is not the soft counterpart to scientific rigor or commercial discipline; it functions as the structural mechanism through which companies execute strategy in an ecosystem-based industry.

Where Alliances Really Break Down

The consequences of fragmentation are well documented. How effective the JSC is affects the outcomes alliances achieve, both in the tangible results of goal

Figure 1 – Effectiveness and Outcome Scores by Performance Category

achievement and how alliance team members feel about working with their partners. A meta-analysis of data from The Rhythm of Business’  VitalSigns™ Alliance Operations Effectiveness Assessments of codevelopment and cocommercialization alliances shows that alliances with the most effective JSCs achieve as much as 50 percent better outcomes than the alliances with the least effective JSCs. (See Figure 1 – Effectiveness and Outcomes Scores by Performance Category).

The same challenges recur with regularity. Partners interpret strategic intent differently. Decision-making slows and issues shuttle between governance bodies without resolution, causing value-eroding delays. Structural asymmetries—between large and small organizations or between licensor and licensee—create misaligned expectations and friction. Leaders give inconsistent attention, leaving alliance teams to resolve issues without the authority required to address root causes. These patterns suggest a deeper reality: collaboration breaks not at the point of execution, but at the point of leadership.

These factors operate quietly at first, often masked by productive interpersonal relationships or early enthusiasm. But as scientific, operational, or market realities evolve, the absence of strategic alignment, unresolved structural tension, and lack of executive leadership becomes increasingly visible. Alliances struggle not because teams lack goodwill, but because companies never baked the conditions required for collaboration into daily operations.

The Leadership Cascade: From C-Suite to Alliance Team

Figure 2 – Leadership Cascade

Does the lack of collaborative capability in the C-suite that Gartner identified serve as the upstream source of these conditions? Collaboration inside an alliance does not begin at the Joint Steering Committee or with the alliance manager. Leaders plant the roots much earlier, within the organization’s leadership system, which either enables or impedes collaboration. The C-suite establishes the strategic narrative that guides all alliances, clarifies the priorities that anchor decision-making, and signals the partnership behaviors that will—or will not—reward. (See Figure 2 – Leadership Cascade).

The leadership system enables an organization to develop collaborative capability that extends beyond the alliance management function and becomes a strategic architecture embedded throughout the enterprise. It integrates mindset, skillset, and toolset (See Figure 3 – Collaborative Capability). It institutionalizes collaboration as a strategic way of working. It prepares teams to identify, diagnose, and resolve issues early. It enables executives to act with clarity and joint teams to operate as one. It connects alliance performance to enterprise value rather than treating it as a peripheral activity. Value does not simply emerge from the science or the contract—leaders create value through the surrounding leadership system.

Figure 3 – Collaborative Capability

Reshaping the Leadership System to Be Collaborative

No one-size-fits-all leadership system exists because organizations exercise leadership differently based on structure and purpose. Figure 4 depicts the elements that constitute a typical leadership system shaped to be collaborative. Organizations embed their leadership system in processes and culture. People rarely discuss it, but it shows up in every aspect of an organization, including structural and cultural barriers to collaboration and partnering. These barriers cause much of the friction and inefficiencies in partnering and leaders must remove them.

Leadership systems operate at many levels: a manager incentivizes her department, a team leader encourages accountability, and an alliance governance structure aligns its decision-making calendar with the internal governance calendars of the partners. Alliance and partner professionals influence – and in some instances control – how leaders implement these elements, and they can do so in ways that advance a collaborative agenda.

Figure 4 – Characteristics of a Collaborative Leadership System

Collaboration as the Basis of Advantage

Scientific innovation will not alone determine the biopharma industry’s future; collaborative capability will. Companies with the most advanced science will falter if they cannot collaborate across boundaries. Companies with less internal scale will outperform when they leverage the ecosystem more effectively. Organizations that treat collaboration as a strategic discipline—measure it, reinforce it, and model it from the top—will define the next era of biomedical progress.

Alliance leadership no longer falls to a single function; executives must treat it as a corporate strategic imperative. Organizations will thrive when executives lead with coherence and collaborative conviction, when leadership systems operate with unity and discipline, and when alliance teams can translate strategy into sustained value.

For alliance professionals, the challenge lies in raising awareness of what success requires in a collaborative business model, especially among the senior executives they’ve worked hard to earn the right to influence. Capture examples of how the leadership system incentivizes non-collaborative behavior and show the impact on value. Propose change. Give your JSC-serving executives opportunities to build their collaborative fluency both among themselves and with alliance partners. Drive efficient operations to demonstrate the additive nature of true collaboration. In a world where alliances determine competitive position, collaborative capability does not merely matter. It decides outcomes.

[1] “Does Your C-Suite Really Operate as a Team?” Harvard Business Review, November-December 2025.